Study wrapper · #947
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Giblin K, Kaplan LM, Somers VK, et al. Diabetes, obesity & metabolism. 2026.
DOI: 10.1111/dom.70209PubMed: 41090431
Editor's note
This paper lays out the rationale and novel basket-trial design of the Phase 3 TRIUMPH program for retatrutide, spanning obesity, sleep apnea, and knee osteoarthritis. It reports study structure and endpoints rather than results, which are still to come. A significant registrational program worth tracking, with no efficacy data yet.
Plain-language abstract
A design paper describing the TRIUMPH Phase 3 program, which is evaluating retatrutide for weight management and two obesity-related complications, obstructive sleep apnea and knee osteoarthritis, across more than 5,800 participants.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026